Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tongxiening Granule for diarrhea-predominant irritable bowel syndrome related to psychological factors
ChiCTR1900023224Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Tongxiening Granule in Diarrhea-predominant irritable bowel syndrome (IBS-D) (2 arms), sponsored by The First Affiliated Hospital of USTC. Primary endpoints: Symptom severity score, IBS quality of life score and 3 more. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
Tongxiening Granule
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on ChiCTR1900023224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023224.